Skip to main content

Loading market data...

ABT

Abbott Laboratories

NYSE • United states

$104.06

-$0.83

(-0.79%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:03 GMT+0000

Management
Credibility
Score

Abbott Laboratories (ABT)

Unavailable

Quotes may be delayed

$180.06B

Market Cap

7,883,828

Volume

28.7

P/E Ratio

2.51%

Div Yield

Abbott Laboratories Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

21 Oct 2026

Abbott Laboratories reported Another company event

Abbott Laboratories filed an 8-K covering another company event, supporting financial statements or exhibits.

21 Oct 2026

Abbott Laboratories reported Operating or financial results

Abbott Laboratories filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

20 Aug 2026

Abbott Laboratories reported Regulation FD disclosure

Abbott Laboratories filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

28 Jul 2026

Abbott Laboratories filed Form 10-Q

Abbott Laboratories submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

16 Jul 2026

Abbott Laboratories reported Operating or financial results

Abbott Laboratories filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$6.80B

Total assets (USD)$110.43B

Shareholders' equity (USD)$52.06B

Long-term debt (USD)$29.64B

Debt due within a year (USD)$4.41B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 31 Mar 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2026	$11.16B	$1.35B	$1.08B	$0.61	10-Q · 29 Apr 2026
Q4 2025	$11.46B	$2.25B	$1.78B	Unavailable	10-K · 20 Feb 2026
Q3 2025	$11.37B	$2.06B	$1.64B	$0.94	10-Q · 29 Oct 2025
Q2 2025	$11.14B	$2.05B	$1.78B	$1.01	10-Q · 30 Jul 2025
Q1 2025	$10.36B	$1.69B	$1.33B	$0.76	10-Q · 30 Apr 2025
Q4 2024	$10.97B	$1.91B	$9.23B	Unavailable	10-K · 21 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $125.50

20.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

13

⏸️

Hold

0

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 10:49 UTC Targets range 112.00–135.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

23

Sep 2026

Conroy Kevin T

Director

Tax withholding

$103.99 per share

52,507 shares

2

Sep 2026

MCCOY JOHN A. JR.

VICE PRESIDENT AND CONTROLLER

Open-market sale

$109.54 per share

27 shares

1

Sep 2026

MCCOY JOHN A. JR.

VICE PRESIDENT AND CONTROLLER

Tax withholding

$110.36 per share

52 shares

1

Sep 2026

Boudreau Philip P

EVP AND CFO

Tax withholding

$110.36 per share

388 shares

Top Shareholders

Vanguard Group Inc

175,556,716 shares

1.387% change

12/31/2025

Blackrock, Inc.

152,563,476 shares

4.72% change

6/30/2026

Vanguard Capital Management Llc

113,750,994 shares

0.709% change

6/30/2026

State Street Corp

80,926,234 shares

1.697% change

6/30/2026

Charles Schwab Investment Management Inc

59,674,507 shares

31.153% change

6/30/2026

Vanguard Portfolio Management Llc

49,017,866 shares

2.238% change

6/30/2026

Geode Capital Management, Llc

39,219,337 shares

0.18% change

6/30/2026

Capital Research Global Investors

36,908,990 shares

-25.849% change

6/30/2026

Capital International Investors

34,654,113 shares

-7.585% change

6/30/2026

Morgan Stanley

26,611,315 shares

-11.595% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 10:49 UTC· 1 day ago

Research coverage and investment tools

Abbott Laboratories (ABT) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$104.06 on 19 Oct 2026. That is 44% of the way from its 52-week low of US$81.97 to its 52-week high of US$132.03. It paid US$2.52 a share in dividends over the last 12 months, a dividend yield of 2.51%. The latest ex-dividend date on file is 15 Oct 2026. Its market capitalisation was US$180.06 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2026	$11.16B	$1.35B	$1.08B	$0.61	—	12.0%	$916.00M	10-Q · 29 Apr 2026 (opens in a new tab)
Q4 2025	$11.46B	$2.25B	$1.78B	Unavailable	—	19.6%	$2.63B	10-K · 20 Feb 2026 (opens in a new tab)
Q3 2025	$11.37B	$2.06B	$1.64B	$0.94	—	18.1%	$2.29B	10-Q · 29 Oct 2025 (opens in a new tab)
Q2 2025	$11.14B	$2.05B	$1.78B	$1.01	—	18.4%	$1.55B	10-Q · 30 Jul 2025 (opens in a new tab)
Q1 2025	$10.36B	$1.69B	$1.33B	$0.76	—	16.3%	$933.00M	10-Q · 30 Apr 2025 (opens in a new tab)
Q4 2024	$10.97B	$1.91B	$9.23B	Unavailable	—	17.4%	$2.15B	10-K · 21 Feb 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/16/2026	$1.31	$1.28	+2.3%
Mar 2026	4/16/2026	$1.15	$1.14	+0.9%
Dec 2025	1/22/2026	$1.50	$1.50	0.0%
Sep 2025	10/15/2025	$1.30	$1.30	0.0%

Cash and equivalents: $6.80B
Total assets: $110.43B
Shareholders' equity: $52.06B
Long-term debt: $29.64B
Debt due within a year: $4.41B

8-K · 21 Oct 2026

Abbott Laboratories reported Another company event (opens in a new tab)

Abbott Laboratories filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 21 Oct 2026

Abbott Laboratories reported Operating or financial results (opens in a new tab)

Abbott Laboratories filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 20 Aug 2026

Abbott Laboratories reported Regulation FD disclosure (opens in a new tab)

Abbott Laboratories filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.
10-Q · 28 Jul 2026

Abbott Laboratories filed Form 10-Q (opens in a new tab)

Abbott Laboratories submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 16 Jul 2026

Abbott Laboratories reported Operating or financial results (opens in a new tab)

Abbott Laboratories filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Conroy Kevin T Director	23 Sep 2026	Tax withholding (F)	−52,507	$103.99	Form 4 (opens in a new tab)
MCCOY JOHN A. JR. VICE PRESIDENT AND CONTROLLER	2 Sep 2026	Open-market sale (S)	−27	$109.54	Form 4 (opens in a new tab)
MCCOY JOHN A. JR. VICE PRESIDENT AND CONTROLLER	1 Sep 2026	Tax withholding (F)	−52	$110.36	Form 4 (opens in a new tab)
Boudreau Philip P EVP AND CFO	1 Sep 2026	Tax withholding (F)	−388	$110.36	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	175,556,716	1.387%
Blackrock, Inc.	6/30/2026	152,563,476	4.72%
Vanguard Capital Management Llc	6/30/2026	113,750,994	0.709%
State Street Corp	6/30/2026	80,926,234	1.697%
Charles Schwab Investment Management Inc	6/30/2026	59,674,507	31.153%
Vanguard Portfolio Management Llc	6/30/2026	49,017,866	2.238%
Geode Capital Management, Llc	6/30/2026	39,219,337	0.18%
Capital Research Global Investors	6/30/2026	36,908,990	-25.849%
Capital International Investors	6/30/2026	34,654,113	-7.585%
Morgan Stanley	6/30/2026	26,611,315	-11.595%

Previous close: 104.89 USD
Day range: 103.54 – 104.87 USD
52-week range: 81.97 – 132.03 USD
Volume: 7,883,828
Market cap: $180.06B
Average volume: 5,447,818
P/E ratio: 28.7
EPS (FY 2025, diluted): 3.72 USD
Dividends (last 12 months): 2.52 USD
Dividend yield: 2.51%
Ex-dividend date: 15 Oct 2026
Shares outstanding: 1.73B
Beta (5Y monthly): 0.56

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:03 UTC· 2 days ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:06 UTC· 35 minutes ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 08:06 UTC· 35 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for ABT yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.